<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> are categorized to the three main categories myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPN), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN overlap </plain></SENT>
<SENT sid="1" pm="."><plain>So far, no specific genetic alteration profiles have been identified in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN overlap category </plain></SENT>
<SENT sid="2" pm="."><plain>Recent studies identified mutations in SETBP1 as novel marker in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>, especially in atypical <z:mp ids='MP_0005481'>CML</z:mp> (aCML) and related diseases </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed SETBP1 in 1,130 patients with MPN and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN overlap and found mutation frequencies of 3.8% and 9.4%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>In particular, there was a high frequency of SETBP1 mutation in aCML (19/60; 31.7%) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN unclassifiable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN, U) (20/240; 9.3%) </plain></SENT>
<SENT sid="5" pm="."><plain>SETBP1 mutated (SETBP1mut) patients showed significantly higher white blood cell counts and lower platelet counts and <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> levels than SETBP1 <z:mp ids='MP_0002169'>wild-type</z:mp> patients </plain></SENT>
<SENT sid="6" pm="."><plain>Cytomorphologic evaluation revealed a more dysplastic phenotype in SETBP1mut cases as compared to <z:mp ids='MP_0002169'>wild type</z:mp> cases </plain></SENT>
<SENT sid="7" pm="."><plain>We confirm a significant association of SETBP1mut with -7 and isochromosome i(17)(q10) </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, SETBP1mut were strongly associated with ASXL1 and CBL mutations (P&lt;0.001 for both) and were mutually exclusive of JAK2 and TET2 mutations </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, SETBP1mut add an important new diagnostic marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN and in particular for aCML.<z:hpo ids='HP_0001909'>Leukemia</z:hpo> accepted article preview online, 30 April 2013; doi:10.1038/leu.2013.133 </plain></SENT>
</text></document>